-=Vir Biotechnology (VIR) : hepatitis B drug trial results

 

Vir Biotechnology reports initial data from ongoing Phase 1 trial of VIR-3434 for chronic hepatitis B Virus infection demonstrates significant and rapid reduction in hepatitis B surface antigen

Data from the first blinded cohort of eight patients, two of whom received placebo and six of whom received a single dose of 6 mg of VIR-3434, showed that six of eight patients achieved a mean reduction of 1.3 log10 IU/mL in serum hepatitis B virus surface antigen (HBsAg) by day eight, the day when nadir was achieved in most patients.

A Phase 2 trial combining VIR-3434 with Vir's HBV-targeting siRNA, VIR-2218, is expected to commence in the second half of this year.